Literature DB >> 17764063

Sjögren's Syndrome.

Spyros A Papiris1, Ioannis A Tsonis, Haralampos M Moutsopoulos.   

Abstract

Sjögren's syndrome (SS) is a chronic, slowly progressive, inflammatory, autoimmune disease characterized by (1) lymphocytic infiltration of the exocrine glands leading to diminished or absent glandular secretion, and (2) marked B-lymphocytic cell hyperreactivity manifested initially by a variety of serum autoantibodies, including those against the Ro(SSA) and La(SSB) ribonucleoproteins, ending in the development of B cell non-Hodgkin's lymphoma in a substantial number of patients. Most patients with SS present only with keratoconjunctivitis sicca and xerostomia. However, approximately 40% develop extraglandular manifestations that present in two ways: (1) the development of lymphoepithelial lesions in several extra-exocrine gland tissues (i.e., bronchi, renal tubules, or biliary ducts), and (2) vasculitis related to the deposition of immune complexes due to B cell hyperreactivity. Pulmonary manifestations develop in some patients and may present as (1) bronchitis sicca; (2) a wide spectrum of lymphoproliferative diseases, ranging from bronchus-associated lymphoid tissue (BALT) hyperplasia, lymphoid interstitial pneumonia, and B cell non-Hodgkin's lymphoma mainly of the extranodal marginal zone B-cell lymphoma of BALT-type or rarely of higher-grade malignancy; and (3) other interstitial pneumonias. Pleuritis can be seen in SS patients with associated systemic lupus erythematosus or rheumatoid arthritis.

Entities:  

Mesh:

Year:  2007        PMID: 17764063     DOI: 10.1055/s-2007-985667

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  6 in total

Review 1.  Sjögren syndrome.

Authors:  Clio P Mavragani; Haralampos M Moutsopoulos
Journal:  CMAJ       Date:  2014-02-24       Impact factor: 8.262

2.  The clinical significance of anti-cyclic citrullinated peptide antibody in primary Sjögren syndrome.

Authors:  So-Mi Kim; Eugene Park; Jung-Hwa Lee; Sang-Heon Lee; Hae-Rim Kim
Journal:  Rheumatol Int       Date:  2011-12-29       Impact factor: 2.631

3.  Proteomic analysis of saliva: a unique tool to distinguish primary Sjögren's syndrome from secondary Sjögren's syndrome and other sicca syndromes.

Authors:  Chiara Baldini; Laura Giusti; Federica Ciregia; Ylenia Da Valle; Camillo Giacomelli; Elena Donadio; Francesca Sernissi; Laura Bazzichi; Gino Giannaccini; Stefano Bombardieri; Antonio Lucacchini
Journal:  Arthritis Res Ther       Date:  2011-11-25       Impact factor: 5.156

4.  Lung fibrosis in autoimmune diseases and hypersensitivity: how to separate these from idiopathic pulmonary fibrosis.

Authors:  Helmut Popper; Elvira Stacher-Priehse; Luka Brcic; Andreas Nerlich
Journal:  Rheumatol Int       Date:  2021-10-04       Impact factor: 3.580

5.  Autoantibody to NA14 is an independent marker primarily for Sjogren's syndrome.

Authors:  Kazuhisa Nozawa; Keigo Ikeda; Minoru Satoh; Westley H Reeves; Carol M Stewart; Yueh-Chun Li; Tim J Yen; Rosa M Rios; Kenji Takamori; Hideoki Ogawa; Iwao Sekigawa; Yoshinari Takasaki; Edward K L Chan
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

6.  Anti-cyclic citrullinated peptide antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis.

Authors:  Fabiola Atzeni; Piercarlo Sarzi-Puttini; Nicola Lama; Eleonora Bonacci; Francesca Bobbio-Pallavicini; Carlomaurizio Montecucco; Roberto Caporali
Journal:  Arthritis Res Ther       Date:  2008-05-07       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.